This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

6 Large-Cap Stocks to Consider

4. Teva Pharmaceutical is an Israel-based maker of generic drugs, specialty pharmaceuticals and pharmaceutical ingredients. It's the largest generic drug maker in the world.

Net revenue reported for the second quarter was $4.2 billion, up 11% from the corresponding period in 2010. The Gross profit margin during fourth quarter of 2010 was a healthy 57.3%. The company's cash flow from operations stood at $1.3 billion, along with free cash flow of $897 million.

Teva's performance during the second quarter saw increased contributions from its European business. It also saw double-digit growth in markets like Latin America and Asia. Strong growth was observed in several branded franchises like women's health.

Another positive is the settlement of patent litigation in relation to the launch of generic Lotrel and generic Neurontin.

Revenue guidance for fiscal 2011 stood at $18.5 billion to $19 billion, with EPS ranging from $4.90 to $5.20.

On average, analysts expect the stock to gain 63% over the next year. Seventy-nine percent of analysts rate the stock a buy. Shares are trading at a P/E of 7 based on estimated 2011 earnings.
3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
E $32.77 0.00%
JPM $63.20 0.00%
ITUB $9.53 0.00%
PBR $7.71 0.00%
RIO $33.66 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs